利奈唑胺对一线抗结核药物敏感或耐药的结核分枝杆菌临床分离株的体外活性。
In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs.
作者信息
Alcalá Luis, Ruiz-Serrano María Jesús, Pérez-Fernández Turégano Cristina, García De Viedma Darío, Díaz-Infantes Marisol, Marín-Arriaza Mercedes, Bouza Emilio
机构信息
Servicio de Microbiología y Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
出版信息
Antimicrob Agents Chemother. 2003 Jan;47(1):416-7. doi: 10.1128/AAC.47.1.416-417.2003.
Abstract
We evaluated 117 isolates of Mycobacterium tuberculosis for susceptibility to linezolid by the proportion and E-test methods. Linezolid showed high in vitro activity, with all the strains inhibited by <or=1 microg of the drug per ml. E-test MICs were at least 4 dilutions lower than their equivalents by the standard proportion method.
摘要
我们通过比例法和E-test法评估了117株结核分枝杆菌对利奈唑胺的敏感性。利奈唑胺显示出较高的体外活性，所有菌株均被每毫升≤1微克的该药物所抑制。E-test法测得的最低抑菌浓度（MIC）比标准比例法测得的等效浓度至少低4倍稀释度。
相似文献
1
In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs.利奈唑胺对一线抗结核药物敏感或耐药的结核分枝杆菌临床分离株的体外活性。
Antimicrob Agents Chemother. 2003 Jan;47(1):416-7. doi: 10.1128/AAC.47.1.416-417.2003.
2
First linezolid-resistant clinical isolates of Mycobacterium tuberculosis.耐利奈唑胺的结核分枝杆菌临床分离株。
Antimicrob Agents Chemother. 2007 Apr;51(4):1534-6. doi: 10.1128/AAC.01113-06. Epub 2007 Jan 22.
3
In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis complex isolated in Taiwan over 10 years.利奈唑胺对台湾地区10余年间分离的结核分枝杆菌复合群临床分离株的体外活性。
Antimicrob Agents Chemother. 2008 Jun;52(6):2226-7. doi: 10.1128/AAC.00414-07. Epub 2008 Apr 7.
4
In vitro activity of linezolid against clinical isolates of Mycobacterium tuberculosis, including multidrug-resistant and extensively drug-resistant strains from Beijing, China.利奈唑胺对包括来自中国北京的耐多药和广泛耐药结核分枝杆菌临床分离株的体外活性。
Jpn J Infect Dis. 2012;65(3):240-2. doi: 10.7883/yoken.65.240.
5
6
In vitro activities of PNU-100480 and linezolid against drug-susceptible and drug-resistant Mycobacterium tuberculosis isolates.
Int J Antimicrob Agents. 2013 Jul;42(1):96-7. doi: 10.1016/j.ijantimicag.2013.03.002. Epub 2013 May 15.
7
In vitro activity of linezolid against Mycobacterium tuberculosis strains isoalted from Western Turkey.利奈唑胺对从土耳其西部分离出的结核分枝杆菌菌株的体外活性。
Jpn J Infect Dis. 2009 Sep;62(5):384-5.
8
[Evaluation of the mycobacterium efficacy of linezolid in vitro].[利奈唑胺体外抗分枝杆菌效果的评估]
Zhonghua Jie He He Hu Xi Za Zhi. 2011 Aug;34(8):575-8.
9
[Evaluation of second-line antituberculosis drug susceptibilities of multidrug-resistant Mycobacterium tuberculosis complex isolates by E-test method].[采用E-test法评估耐多药结核分枝杆菌复合群分离株的二线抗结核药物敏感性]
Mikrobiyol Bul. 2015 Jan;49(1):47-55. doi: 10.5578/mb.8602.
10
In vitro susceptibility of Mycobacterium tuberculosis clinical isolates to garenoxacin and DA-7867.结核分枝杆菌临床分离株对加雷沙星和DA-7867的体外敏感性
Antimicrob Agents Chemother. 2005 Oct;49(10):4351-3. doi: 10.1128/AAC.49.10.4351-4353.2005.
引用本文的文献
1
Deciphering linezolid-induced hematologic toxicity: Targeting TOP2A and TOP2B via its primary metabolite PNU142586.解读利奈唑胺诱导的血液学毒性：通过其主要代谢产物PNU142586靶向TOP2A和TOP2B。
Sci Adv. 2025 May 30;11(22):eadt5833. doi: 10.1126/sciadv.adt5833. Epub 2025 May 28.
2
Dual Mutations in and Confer High-Level Resistance to Bortezomib and Linezolid by Both Reducing Drug Intake and Increasing Efflux in .和中的双重突变通过减少药物摄取和增加中的外排赋予对硼替佐米和利奈唑胺的高水平抗性。
Int J Mol Sci. 2025 Apr 17;26(8):3779. doi: 10.3390/ijms26083779.
3
The antimicrobial activity of linezolid against unconventional pathogens.利奈唑胺对非传统病原体的抗菌活性。
PeerJ. 2025 Feb 12;13:e18825. doi: 10.7717/peerj.18825. eCollection 2025.
4
New Oxazolidinones for Tuberculosis: Are Novel Treatments on the Horizon?用于治疗结核病的新型恶唑烷酮类药物：新的治疗方法即将出现？
Pharmaceutics. 2024 Jun 17;16(6):818. doi: 10.3390/pharmaceutics16060818.
5
Differential distribution of linezolid in diseased and nondiseased bones in patients with spinal tuberculosis.利奈唑胺在脊柱结核患者病变和非病变骨中的差异分布。
BMC Infect Dis. 2024 Jan 5;24(1):50. doi: 10.1186/s12879-023-08970-x.
6
Linezolid does not improve bactericidal activity of rifampin-containing first-line regimens in animal models of TB meningitis.利奈唑胺并不能提高含利福平的一线方案在结核性脑膜炎动物模型中的杀菌活性。
Int J Antimicrob Agents. 2024 Jan;63(1):107048. doi: 10.1016/j.ijantimicag.2023.107048. Epub 2023 Dec 5.
7
Contemporary Pharmacotherapies for Nontuberculosis Mycobacterial Infections: A Narrative Review.非结核分枝杆菌感染的当代药物治疗：一项叙述性综述
Infect Dis Ther. 2023 Feb;12(2):343-365. doi: 10.1007/s40121-022-00750-5. Epub 2023 Jan 7.
8
New and Repurposed Drugs for the Treatment of Active Tuberculosis: An Update for Clinicians.新型和再利用药物治疗活动性结核病：临床医生的最新进展。
Respiration. 2023;102(2):83-100. doi: 10.1159/000528274. Epub 2022 Dec 14.
9
Acyldepsipeptide Analogues: A Future Generation Antibiotics for Tuberculosis Treatment.酰基二肽类似物：用于结核病治疗的新一代抗生素。
Pharmaceutics. 2022 Sep 15;14(9):1956. doi: 10.3390/pharmaceutics14091956.
10
Linezolid resistance in multidrug-resistant mycobacterium tuberculosis: A systematic review and meta-analysis.耐多药结核分枝杆菌对利奈唑胺的耐药性：一项系统评价和荟萃分析。
Front Pharmacol. 2022 Aug 30;13:955050. doi: 10.3389/fphar.2022.955050. eCollection 2022.
本文引用的文献
1
Antituberculosis drugs and new drug development.抗结核药物与新药研发
Curr Opin Pulm Med. 2001 May;7(3):142-7. doi: 10.1097/00063198-200105000-00005.
2
[Multiresistant tuberculosis caused by Mycobacterium bovis and human immunodeficiency virus infection. Are there new therapeutic possibilities?].[牛分枝杆菌引起的多重耐药结核病与人类免疫缺陷病毒感染。是否有新的治疗可能性？]
Enferm Infecc Microbiol Clin. 2001 Jan;19(1):37-9.
3
In vitro activity of linezolid against multiply resistant Gram-positive clinical isolates.利奈唑胺对多重耐药革兰氏阳性临床分离株的体外活性。
J Antimicrob Chemother. 2001 Jan;47(1):77-81. doi: 10.1093/jac/47.1.77.
4
Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project.共识声明。全球结核病负担：按国家估算的发病率、患病率和死亡率。世卫组织全球监测项目。
JAMA. 1999 Aug 18;282(7):677-86. doi: 10.1001/jama.282.7.677.
5
Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model.几种新型恶唑烷酮类药物在小鼠模型中对结核分枝杆菌的活性。
Antimicrob Agents Chemother. 1999 May;43(5):1189-91. doi: 10.1128/AAC.43.5.1189.
6
Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions.恶唑烷酮类药物的作用机制：利奈唑胺和依哌唑胺对翻译反应的影响。
Antimicrob Agents Chemother. 1997 Oct;41(10):2132-6. doi: 10.1128/AAC.41.10.2132.
7
In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones.两种新型氟化恶唑烷酮U-100592和U-100766的体外抗菌活性及抗菌谱
Antimicrob Agents Chemother. 1996 Mar;40(3):720-6. doi: 10.1128/AAC.40.3.720.
8
In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents.新型恶唑烷酮类抗菌剂U-100592和U-100766的体外活性
Antimicrob Agents Chemother. 1996 Apr;40(4):839-45. doi: 10.1128/AAC.40.4.839.
Zotero 插件